The next‑gen delivery systems for genetic drug market focuses on cutting-edge platforms such as lipid nanoparticles, viral vectors, and extracellular vesicles to improve safety, targeting, and efficiency of gene and nucleic acid therapies. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Next-Gen Delivery Systems for Genetic Drug Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Next-Gen Delivery Systems for Genetic Drug Market, by Delivery System Type
8.1.1. Lipid-Based Delivery Systems
8.1.1.1. Market Revenue and Forecast
8.1.2. Polymer-Based Delivery Systems
8.1.2.1. Market Revenue and Forecast
8.1.3. Viral Vectors
8.1.3.1. Market Revenue and Forecast
8.1.4. Peptide-Based Delivery System
8.1.4.1. Market Revenue and Forecast
8.1.5. Exosome-Based Delivery Systems
8.1.5.1. Market Revenue and Forecast
8.1.6. Hybrid & Emerging Systems
8.1.6.1. Market Revenue and Forecast
9.1. Next-Gen Delivery Systems for Genetic Drug Market, by Genetic Drug Type
9.1.1. Gene Therapy (DNA-based)
9.1.1.1. Market Revenue and Forecast
9.1.2. RNA-based Therapeutics
9.1.2.1. Market Revenue and Forecast
9.1.3. Gene Editing Tools
9.1.3.1. Market Revenue and Forecast
9.1.4. Oligonucleotide Drugs
9.1.4.1. Market Revenue and Forecast
9.1.5. Aptamers
9.1.5.1. Market Revenue and Forecast
10.1. Next-Gen Delivery Systems for Genetic Drug Market, by Target Organ/Tissue
10.1.1. Liver
10.1.1.1. Market Revenue and Forecast
10.1.2. Muscle
10.1.2.1. Market Revenue and Forecast
10.1.3. CNS (Central Nervous System)
10.1.3.1. Market Revenue and Forecast
10.1.4. Eye
10.1.4.1. Market Revenue and Forecast
10.1.5. Lungs
10.1.5.1. Market Revenue and Forecast
10.1.6. Tumor/Malignant Tissue
10.1.6.1. Market Revenue and Forecast
10.1.7. Others (e.g., skin, cardiovascular)
10.1.7.1. Market Revenue and Forecast
11.1. Next-Gen Delivery Systems for Genetic Drug Market, by Administration Route
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast
11.1.2. Intramuscular (IM)
11.1.2.1. Market Revenue and Forecast
11.1.3. Subcutaneous (SC)
11.1.3.1. Market Revenue and Forecast
11.1.4. Topical
11.1.4.1. Market Revenue and Forecast
11.1.5. Inhalation
11.1.5.1. Market Revenue and Forecast
11.1.6. Intrathecal
11.1.6.1. Market Revenue and Forecast
11.1.7. Oral
11.1.7.1. Market Revenue and Forecast
12.1. Next-Gen Delivery Systems for Genetic Drug Market, by Application
12.1.1. Rare Genetic Disorders
12.1.1.1. Market Revenue and Forecast
12.1.2. Oncology
12.1.2.1. Market Revenue and Forecast
12.1.3. Neurology
12.1.3.1. Market Revenue and Forecast
12.1.4. Infectious Diseases
12.1.4.1. Market Revenue and Forecast
12.1.5. Metabolic Disorders
12.1.5.1. Market Revenue and Forecast
12.1.6. Cardiovascular Diseases
12.1.6.1. Market Revenue and Forecast
12.1.7. Others
12.1.7.1. Market Revenue and Forecast
13.1. Next-Gen Delivery Systems for Genetic Drug Market, by End-User
13.1.1. Biopharmaceutical Companies
13.1.1.1. Market Revenue and Forecast
13.1.2. Academic & Research Institutes
13.1.2.1. Market Revenue and Forecast
13.1.3. Contract Research Organizations (CROs)
13.1.3.1. Market Revenue and Forecast
13.1.4. Hospitals & Specialized Clinics
13.1.4.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Delivery System Type
14.1.2. Market Revenue and Forecast, by Genetic Drug Type
14.1.3. Market Revenue and Forecast, by Target Organ/Tissue
14.1.4. Market Revenue and Forecast, by Administration Route
14.1.5. Market Revenue and Forecast, by Application
14.1.6. Market Revenue and Forecast, by End-User
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Delivery System Type
14.1.7.2. Market Revenue and Forecast, by Genetic Drug Type
14.1.7.3. Market Revenue and Forecast, by Target Organ/Tissue
14.1.7.4. Market Revenue and Forecast, by Administration Route
14.1.8. Market Revenue and Forecast, by Application
14.1.8.1. Market Revenue and Forecast, by End-User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Delivery System Type
14.1.9.2. Market Revenue and Forecast, by Genetic Drug Type
14.1.9.3. Market Revenue and Forecast, by Target Organ/Tissue
14.1.9.4. Market Revenue and Forecast, by Administration Route
14.1.10. Market Revenue and Forecast, by Application
14.1.11. Market Revenue and Forecast, by End-User
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Delivery System Type
14.2.2. Market Revenue and Forecast, by Genetic Drug Type
14.2.3. Market Revenue and Forecast, by Target Organ/Tissue
14.2.4. Market Revenue and Forecast, by Administration Route
14.2.5. Market Revenue and Forecast, by Application
14.2.6. Market Revenue and Forecast, by End-User
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Delivery System Type
14.2.8.2. Market Revenue and Forecast, by Genetic Drug Type
14.2.8.3. Market Revenue and Forecast, by Target Organ/Tissue
14.2.9. Market Revenue and Forecast, by Administration Route
14.2.10. Market Revenue and Forecast, by Application
14.2.10.1. Market Revenue and Forecast, by End-User
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Delivery System Type
14.2.11.2. Market Revenue and Forecast, by Genetic Drug Type
14.2.11.3. Market Revenue and Forecast, by Target Organ/Tissue
14.2.12. Market Revenue and Forecast, by Administration Route
14.2.13. Market Revenue and Forecast, by Application
14.2.14. Market Revenue and Forecast, by End-User
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Delivery System Type
14.2.15.2. Market Revenue and Forecast, by Genetic Drug Type
14.2.15.3. Market Revenue and Forecast, by Target Organ/Tissue
14.2.15.4. Market Revenue and Forecast, by Administration Route
14.2.16. Market Revenue and Forecast, by Application
14.2.16.1. Market Revenue and Forecast, by End-User
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Delivery System Type
14.2.17.2. Market Revenue and Forecast, by Genetic Drug Type
14.2.17.3. Market Revenue and Forecast, by Target Organ/Tissue
14.2.17.4. Market Revenue and Forecast, by Administration Route
14.2.18. Market Revenue and Forecast, by Application
14.2.18.1. Market Revenue and Forecast, by End-User
14.3. APAC
14.3.1. Market Revenue and Forecast, by Delivery System Type
14.3.2. Market Revenue and Forecast, by Genetic Drug Type
14.3.3. Market Revenue and Forecast, by Target Organ/Tissue
14.3.4. Market Revenue and Forecast, by Administration Route
14.3.5. Market Revenue and Forecast, by Application
14.3.6. Market Revenue and Forecast, by End-User
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Delivery System Type
14.3.7.2. Market Revenue and Forecast, by Genetic Drug Type
14.3.7.3. Market Revenue and Forecast, by Target Organ/Tissue
14.3.7.4. Market Revenue and Forecast, by Administration Route
14.3.8. Market Revenue and Forecast, by Application
14.3.9. Market Revenue and Forecast, by End-User
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Delivery System Type
14.3.10.2. Market Revenue and Forecast, by Genetic Drug Type
14.3.10.3. Market Revenue and Forecast, by Target Organ/Tissue
14.3.10.4. Market Revenue and Forecast, by Administration Route
14.3.11. Market Revenue and Forecast, by Application
14.3.11.1. Market Revenue and Forecast, by End-User
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Delivery System Type
14.3.12.2. Market Revenue and Forecast, by Genetic Drug Type
14.3.12.3. Market Revenue and Forecast, by Target Organ/Tissue
14.3.12.4. Market Revenue and Forecast, by Administration Route
14.3.12.5. Market Revenue and Forecast, by Application
14.3.12.6. Market Revenue and Forecast, by End-User
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Delivery System Type
14.3.13.2. Market Revenue and Forecast, by Genetic Drug Type
14.3.13.3. Market Revenue and Forecast, by Target Organ/Tissue
14.3.13.4. Market Revenue and Forecast, by Administration Route
14.3.13.5. Market Revenue and Forecast, by Application
14.3.13.6. Market Revenue and Forecast, by End-User
14.4. MEA
14.4.1. Market Revenue and Forecast, by Delivery System Type
14.4.2. Market Revenue and Forecast, by Genetic Drug Type
14.4.3. Market Revenue and Forecast, by Target Organ/Tissue
14.4.4. Market Revenue and Forecast, by Administration Route
14.4.5. Market Revenue and Forecast, by Application
14.4.6. Market Revenue and Forecast, by End-User
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Delivery System Type
14.4.7.2. Market Revenue and Forecast, by Genetic Drug Type
14.4.7.3. Market Revenue and Forecast, by Target Organ/Tissue
14.4.7.4. Market Revenue and Forecast, by Administration Route
14.4.8. Market Revenue and Forecast, by Application
14.4.9. Market Revenue and Forecast, by End-User
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Delivery System Type
14.4.10.2. Market Revenue and Forecast, by Genetic Drug Type
14.4.10.3. Market Revenue and Forecast, by Target Organ/Tissue
14.4.10.4. Market Revenue and Forecast, by Administration Route
14.4.11. Market Revenue and Forecast, by Application
14.4.12. Market Revenue and Forecast, by End-User
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Delivery System Type
14.4.13.2. Market Revenue and Forecast, by Genetic Drug Type
14.4.13.3. Market Revenue and Forecast, by Target Organ/Tissue
14.4.13.4. Market Revenue and Forecast, by Administration Route
14.4.13.5. Market Revenue and Forecast, by Application
14.4.13.6. Market Revenue and Forecast, by End-User
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Delivery System Type
14.4.14.2. Market Revenue and Forecast, by Genetic Drug Type
14.4.14.3. Market Revenue and Forecast, by Target Organ/Tissue
14.4.14.4. Market Revenue and Forecast, by Administration Route
14.4.14.5. Market Revenue and Forecast, by Application
14.4.14.6. Market Revenue and Forecast, by End-User
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Delivery System Type
14.5.2. Market Revenue and Forecast, by Genetic Drug Type
14.5.3. Market Revenue and Forecast, by Target Organ/Tissue
14.5.4. Market Revenue and Forecast, by Administration Route
14.5.5. Market Revenue and Forecast, by Application
14.5.6. Market Revenue and Forecast, by End-User
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Delivery System Type
14.5.7.2. Market Revenue and Forecast, by Genetic Drug Type
14.5.7.3. Market Revenue and Forecast, by Target Organ/Tissue
14.5.7.4. Market Revenue and Forecast, by Administration Route
14.5.8. Market Revenue and Forecast, by Application
14.5.8.1. Market Revenue and Forecast, by End-User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Delivery System Type
14.5.9.2. Market Revenue and Forecast, by Genetic Drug Type
14.5.9.3. Market Revenue and Forecast, by Target Organ/Tissue
14.5.9.4. Market Revenue and Forecast, by Administration Route
14.5.9.5. Market Revenue and Forecast, by Application
14.5.9.6. Market Revenue and Forecast, by End-User
15.1. Moderna, Inc.
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. BioNTech SE
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Alnylam Pharmaceuticals
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Ionis Pharmaceuticals
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Intellia Therapeutics
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. CRISPR Therapeutics
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Editas Medicine
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Beam Therapeutics
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Precision NanoSystems
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Arcturus Therapeutics
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description